Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News CytomX Therapeutics Inc. CTMX

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platform. The company probody technology platform to create proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting...

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:CTMX)

Fundamentals Snapshot (NDAQ:CTMX)

Opinion & Analysis (NDAQ:CTMX)

No current opinion is available.

Bullboard Posts (NDAQ:CTMX)

From boom to boot

Nice rise throughoutthe week, adn then last trad of the day on the 1st for 780,00 shars at whatever the market would get for it...
zalmonella - February 2, 2022

EMERGING PARADIGMS IN TREATMENT OF MELANOMA!

$CTMX $NKTR $MGNX $IDYA $ALKS Melanoma, a form of skin cancer, accounts for about 1% of skin cancers but is responsible for over 7...
AviseAnalytics - January 26, 2022